Literature DB >> 28302510

Bishomoisoprenoid triazole bisphosphonates as inhibitors of geranylgeranyl diphosphate synthase.

Veronica S Wills1, Joseph I Metzger1, Cheryl Allen2, Michelle L Varney3, David F Wiemer4, Sarah A Holstein5.   

Abstract

Protein geranylgeranylation reactions are dependent on the availability of geranylgeranyl diphosphate (GGDP), which serves as the isoprenoid donor. Inhibition of GGDP synthase (GGDPS) is of interest from a drug development perspective as GGDPS inhibition results in impaired protein geranylgeranylation, which in multiple myeloma, disrupts monoclonal protein trafficking and induces apoptosis. We have recently reported a series of isoprenoid triazole bisphosphonates and have demonstrated that a 3:1 mixture of homogeranyl and homoneryl isomers potently, and in a synergistic manner, inhibits GGDPS. We now present the synthesis and biological evaluation of a novel series of bishomoisoprenoid triazoles which furthers our understanding of the structure-function relationship of this class. These studies demonstrate the importance of chain length and olefin stereochemistry on inhibitory activity.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bishomoisoprenoids; Bisphosphonate; GGDP synthase; Inhibition; Isoprenoid biosynthesis; Triazole

Mesh:

Substances:

Year:  2017        PMID: 28302510      PMCID: PMC5450914          DOI: 10.1016/j.bmc.2017.02.066

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  27 in total

Review 1.  Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies.

Authors:  Ting-Chao Chou
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

Review 2.  Is there a future for prenyltransferase inhibitors in cancer therapy?

Authors:  Sarah A Holstein; Raymond J Hohl
Journal:  Curr Opin Pharmacol       Date:  2012-07-18       Impact factor: 5.547

3.  Stereoselective Synthesis of Homoneryl and Homogeranyl Triazole Bisphosphonates.

Authors:  Robert A Matthiesen; Veronica S Wills; Joseph I Metzger; Sarah A Holstein; David F Wiemer
Journal:  J Org Chem       Date:  2016-09-20       Impact factor: 4.354

4.  2-(Acyloxy)ethylphosphonate analogues of prenyl pyrophosphates: synthesis and biological characterization.

Authors:  D M Cermak; D F Wiemer; K Lewis; R J Hohl
Journal:  Bioorg Med Chem       Date:  2000-12       Impact factor: 3.641

5.  Stereochemistry of hexenyl radical cyclizations with tert-butyl and related large groups: substituent and temperature effects.

Authors:  Jonathan C Tripp; Carl H Schiesser; Dennis P Curran
Journal:  J Am Chem Soc       Date:  2005-04-20       Impact factor: 15.419

6.  Epoxide-initiated electrophilic cyclization of azides: a novel route for the stereoselective construction of azabicyclic ring systems and total synthesis of (+/-)-indolizidine 167B and 209D.

Authors:  P Ganapati Reddy; Babu Varghese; Sundarababu Baskaran
Journal:  Org Lett       Date:  2003-02-20       Impact factor: 6.005

7.  Exploration of GGTase-I substrate requirements. Part 2: Synthesis and biochemical analysis of novel saturated geranylgeranyl diphosphate analogs.

Authors:  Kayla J Temple; Elia N Wright; Carol A Fierke; Richard A Gibbs
Journal:  Bioorg Med Chem Lett       Date:  2016-06-15       Impact factor: 2.823

8.  Decarboxylative radical azidation using MPDOC and MMDOC esters.

Authors:  Erich Nyfeler; Philippe Renaud
Journal:  Org Lett       Date:  2008-02-14       Impact factor: 6.005

Review 9.  Protein prenylation: unique fats make their mark on biology.

Authors:  Mei Wang; Patrick J Casey
Journal:  Nat Rev Mol Cell Biol       Date:  2016-01-21       Impact factor: 94.444

10.  Mechanisms for autophagy modulation by isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells.

Authors:  Kaitlyn M Dykstra; Cheryl Allen; Ella J Born; Huaxiang Tong; Sarah A Holstein
Journal:  Oncotarget       Date:  2015-12-08
View more
  7 in total

1.  In Vivo Evaluation of Isoprenoid Triazole Bisphosphonate Inhibitors of Geranylgeranyl Diphosphate Synthase: Impact of Olefin Stereochemistry on Toxicity and Biodistribution.

Authors:  Staci L Haney; Yashpal S Chhonker; Michelle L Varney; Geoffrey Talmon; Lynette M Smith; Daryl J Murry; Sarah A Holstein
Journal:  J Pharmacol Exp Ther       Date:  2019-08-16       Impact factor: 4.030

2.  Amides as bioisosteres of triazole-based geranylgeranyl diphosphate synthase inhibitors.

Authors:  Daniel B Goetz; Michelle L Varney; David F Wiemer; Sarah A Holstein
Journal:  Bioorg Med Chem       Date:  2020-06-30       Impact factor: 3.641

3.  α-Methylation enhances the potency of isoprenoid triazole bisphosphonates as geranylgeranyl diphosphate synthase inhibitors.

Authors:  Robert A Matthiesen; Michelle L Varney; Pauline C Xu; Alex S Rier; David F Wiemer; Sarah A Holstein
Journal:  Bioorg Med Chem       Date:  2017-10-19       Impact factor: 3.641

Review 4.  Recent Advances in the Development of Mammalian Geranylgeranyl Diphosphate Synthase Inhibitors.

Authors:  Staci L Haney; Veronica S Wills; David F Wiemer; Sarah A Holstein
Journal:  Molecules       Date:  2017-05-27       Impact factor: 4.411

5.  Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma.

Authors:  Staci L Haney; Michelle L Varney; Jacob T Williams; Lynette M Smith; Geoffrey Talmon; Sarah A Holstein
Journal:  Exp Hematol Oncol       Date:  2022-02-09

Review 6.  CuAAC-ensembled 1,2,3-triazole-linked isosteres as pharmacophores in drug discovery: review.

Authors:  Alisha Rani; Gurjaspreet Singh; Akshpreet Singh; Ubair Maqbool; Gurpreet Kaur; Jandeep Singh
Journal:  RSC Adv       Date:  2020-02-04       Impact factor: 4.036

7.  Impact of α-modifications on the activity of triazole bisphosphonates as geranylgeranyl diphosphate synthase inhibitors.

Authors:  Alisa E R Fairweather; Daniel B Goetz; Chloe M Schroeder; Nazmul H Bhuiyan; Michelle L Varney; David F Wiemer; Sarah A Holstein
Journal:  Bioorg Med Chem       Date:  2021-07-11       Impact factor: 3.461

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.